Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Sanofi and GSK have jointly developed a next-generation COVID-19 booster vaccine candidate, based on Sanofi’s recombinant Beta variant antigen and combined with GSK’s pandemic adjuvant. Both have served as established vaccine platforms that have proven successful against influenza.